Rivaroxaban是医保药物吗？

Rivaroxaban is indicated primarily for the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery. It can also be used in adult patients with non-valvular atrial fibrillation who have one or more risk factors to reduce the risk of stroke and systemic embolism.

So, is Rivaroxaban a Medicare drug?

Xarelto has been included in the "Basic Medical Insurance Drug List" and is a medical insurance drug.

The price of Rivaroxaban in China is as follows: Specification: 10mg-5 tablets/box, priced at approximately $138; Specification: 15mg-7 tablets/box, priced at approximately $199; Specification: 20mg-7 tablets/box, priced at approximately $263$.

The price of Rivaroxaban on the market abroad is: 15mg*28 tablets; the price of 20mg*28 tablets is around 600$. Please consult Medical Companion Travel for price details. In terms of purchase, patients can go abroad to purchase from pharmacies or obtain them through domestic professional overseas medical service organizations (such as Medical Companion Travel).

Rivaroxaban is a small molecule oral anticoagulant jointly developed by Bayer and Johnson & Johnson. It was approved for marketing in Canada and the European Union on September 15 and October 1, 2008 respectively.

Pharmacological effects of Rivaroxaban:

1. This product is a highly selective oral drug that directly inhibits factor xa. It can inhibit the generation of thrombin and the formation of thrombus.

2. Experimental studies have shown that Rivaroxaban has a dose-dependent inhibitory effect on factor xa activity.

3. Rivaroxaban also affects the activity of anti-factor xa, but there is currently no calibration standard.

It should be noted that this product is contraindicated in patients with clinically significant active bleeding, patients with liver disease who have coagulation abnormalities and clinically relevant bleeding risks. Rivaroxaban should be used with caution in patients at risk for bleeding, hepatic impairment, or renal impairment.